PCRX Q2 2023 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$169M+0.0% YoY

Gross Profit

$121M71.6% margin

Operating Income

$40M23.5% margin

Net Income

$26M15.2% margin

EPS (Diluted)

$0.51

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

$43M

Free Cash Flow

$40M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$734M

Stockholders' Equity

$808M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$169M	$169M	+0.0%
Gross Profit	$121M	$119M	+2.1%
Operating Income	$40M	$31M	+27.7%
Net Income	$26M	$20M	+29.6%

Revenue Segments

Product

$169M51%

EXPAREL/bupivacaine liposome injectable suspension

$135M40%

ZILRETTA

$29M9%

Bupivacaine Liposome Injectable Suspension

$695,0000%